Immutep: 81.1% 1-year disease-free survival in sarcoma
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Immutep reported new survival data from the EFTISARC-NEO Phase II trial, which evaluates eftilagimod alfa with pembrolizumab and radiotherapy before surgery for high-risk, resectable soft tissue sarcoma. Forty patients enrolled; 38 underwent surgery and were included in the survival evaluation. 12-month disease-free survival was 81.1%; the 18-month estimate was also 81.1% but remains immature, with follow-up ongoing. Eight of the 38 evaluated patients had recurrence by April 30, 2026.
At 12 months, local recurrence-free survival was 94.1% and distant metastasis-free survival was 86.2%; median follow-up was 19.1 months. Exploratory analyses reported 95.0% 12-month disease-free survival for patients with post-treatment tumour-infiltrating lymphocyte levels above 310 cells/mm², versus 64.9% at lower levels; the results may indicate an association. Immutep is preparing a registration-directed trial, targeting initiation in H2 CY2027 subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources.
Key Figures
Key Terms
disease-free survival (DFS) medical
Kaplan-Meier estimate medical
tumour-infiltrating lymphocytes (TILs) medical
tertiary lymphoid structures (TLS) medical
neoadjuvant treatment medical
MHC Class II agonist technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What disease-free survival did IMMP report from EFTISARC-NEO?
What exploratory biomarker findings did IMMP report?
When is IMMP targeting the start of a registration-directed sarcoma trial?
AI-generated analysis. How Rhea-AI works. Not financial advice.